Thank you for sharing!

Your article was successfully shared with the contacts you provided.

The glaucoma drug Alphagan P is responsible for about $240 million in annual revenue for the pharmaceutical company Allergan Inc. So it’s no surprise that when Apotex Corp. and Exela Pharmsci Inc. told the Food and Drug Administration that they wanted to make generic versions of the drug, Allergan and its lawyers at Fish & Richardson filed patent infringement suits to stop them. The result? An Oct. 23 ruling from Delaware federal district court Chief Judge Gregory Sleet that gives Allergan exclusive rights to make the drug until 2022. By our math, that ruling is worth a few billion to Fish’s client. After an eight-day bench trial last March, Sleet found that the five Allergan patents at issue in the case were valid and enforceable. He also concluded that Allergan had not committed inequitable conduct. The only good news for Apotex and Exela was that he declined to award attorney fees and costs to Allergen. The Fish & Richardson team was led by Jonathan Singer and included William Marsden and Juanita Brooks. According to Singer, at trial Apotex had Katten Muchin Rosenman and Potter Anderson & Corroon. Exela was represented by Bingham McCutchen. We called Katten and Bingham for comment but didn’t hear back.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.